Navigation Links
Milestone achieved toward production of malaria treatment using synthetic biology and fermentation

EMERYVILLE, Calif., March 2, 2009 - Amyris Biotechnologies has announced the publication of an article which reveals the achievement of a significant milestone toward the production of amorphadiene, a precursor of the antimalarial agent artemisinin.

The article, "High-level production of amorpha-4,11-diene, a precursor of the antimalarial agent artemisinin, in Escherichia coli" appears in PLoS ONE, an open-access journal from the Public Library of Science, chronicles the steps taken which enabled Amyris scientists to achieve a crucial milestone in the fight against malaria the production of 25 g/L of amorphadiene through E. coli fermentations.

The production of amorphadiene in E. coli was first described in 2003 but the amount produced was low (50 mg/L). This level was increased to 0.5g/L in 2006, but still 50-fold lower than target production levels. This article describes the interplay of industrial fermentation processes and synthetic biology that achieved the required 50-fold increase in production levels. This milestone acts as proof of concept that commercially relevant concentrations of artemisinin precursors can be produced by microbes for conversion to artemisinin. Publication in PLoS One ensures the information is available free of charge to all nations.

The paper can be found at

The World Health Organization recommends artemisinin-based combination therapies (ACTs) as first-line treatment for malaria. However, supplies of plant-derived artemisinin are subject to the seasonality and volatility common to many plant-based commodities, leading to fluctuations in the price of artemisinin. Commercial scale production of semi-synthetic artemisinin would have the potential to stabilize supply and supplement existing plant-derived materials to create a consistent, high-quality and affordable new source of artemisinin to help meet the projected world-wide demand for ACTs.

The microbial production of Artemisinin precursors was originally demonstrated in the lab of Professor Jay Keasling at the University of California, Berkeley. Dr. Keasling continued the research and founded Amyris to bring the technology to the developing world.

Dr. Jack Newman, a former Post-doc in the Keasling lab and co-founder of Amyris praised the collaboration effort and the potential of the technology. "The enormous amount of work involved on the road from idea through execution is mind-boggling. I'm grateful to the dedicated team of researchers, philanthropists and visionaries that made this happen. They have demonstrated the potential of this technology to make a difference in the world."


Contact: Annika Jensen-Lamka
Amyris Biotechnologies

Related biology news :

1. A new milestone in the GMES Space Component Program successfully achieved
2. Secure Services Corp. Achieves Milestone in United States Identity Protection with the Launch of the SSC SHAPE Card Management Solution
3. A gentle touch for better control, a quantum mechanical con, and milestone PRL papers
4. Missouri Botanical Garden mounts milestone 6 millionth herbarium specimen
5. Bursts of waves drive immune system soldiers toward invaders
6. MIT works toward safer gene therapy
7. A step toward tissue-engineered heart structures for children
8. Research points towards early cancer detection
9. Researchers take first steps towards spinal cord reconstruction following injury
10. Fish farms drive wild salmon populations toward extinction
11. MIT works toward engineered blood vessels
Post Your Comments:
(Date:11/9/2015)... 09, 2015 ... the "Global Law Enforcement Biometrics Market ... --> ) has announced the ... Biometrics Market 2015-2019" report to their ... ( ) has announced the addition ...
(Date:10/29/2015)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce that it has been ... one of only three finalists for a 2015 ... Growing" category. The Tekne Awards honor Minnesota ... innovation and leadership. iMedNet™ eClinical ...
(Date:10/29/2015)... Oct. 29, 2015  Connected health pioneer, Joseph ... explosion of technology-enabled health and wellness, and the business ... The Internet of Healthy Things . ... smartphones even existed, Dr. Kvedar, vice president, Connected Health, ... care delivery, moving care from the hospital or doctor,s ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... --> --> ... by Transparency Market Research, the global non-invasive prenatal testing ... 17.5% during the period between 2014 and 2022. The ... Analysis, Size, Volume, Share, Growth, Trends and Forecast 2014 ... to reach a valuation of US$2.38 bn by 2022. ...
(Date:11/24/2015)... ... November 24, 2015 , ... In harsh industrial ... points for in-line sensors can represent a weak spot where leaking process media ... of retractable sensor housings , which are designed to tolerate extreme process conditions. ...
(Date:11/24/2015)... LOS ANGELES , Nov. 24, 2015 ... a biotechnology company focused on the discovery, development and ... Marban , Ph.D., Chief Executive Officer, is scheduled to ... December 1, 2015 at 10:50 a.m. EST, at The ... York City . . ...
(Date:11/24/2015)... ... , ... Whitehouse Laboratories is pleased to announce that it has completed construction ... dedicated to basic USP 61, USP 62 and USP 51 testing specific to raw ... and micro testing performed by one supplier. Management has formally announced that ...
Breaking Biology Technology: